1ST Biotherapeutics, Inc.
http://www.1stbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From 1ST Biotherapeutics, Inc.
Traversing The Dark Tunnel: Biopharma Stakeholder Survival Strategies
Amid escalating global macroeconomic uncertainties, participants at the recent KoNECT conference in Seoul shared strategies to overcome the current challenges faced by bioventures.
Finance Watch: Have Biopharma IPOs Hit Their Limit?
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Selected Start-Ups (7/06)
In Vivo briefly summarizes the technologies of these recently founded companies: CS-Keys, NERP Technologies, Organ Assist, Sirion Therapeutics, SpeciGen and VEXIM.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- 1STBio
- 1ST Biotherapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice